The FOXA1 protein is a potentially highly sensitive diagnostic marker for small cell carcinoma of the prostate and possibly ...

Butterfly Medical, developer of a proprietary non-surgical solution for BPH (benign prostatic hyperplasia), today announced ...

The raise will support Rivermark’s pivotal trial, while allowing the medtech company to ready its FloStent system for commercialisation.

Epidemiologic studies, primarily done in white men, suggest that a history of clinically-diagnosed prostatitis increases prostate cancer risk, but that histological prostate inflammation decreases ...

Today, the American Urological Association (AUA) released the 2026 Management of Lower Urinary Tract Symptoms (LUTS) Attributed to Benign Prostatic Hyperplasia (BPH) Guideline, providing updated, ...

Finasteride is FDA-approved to treat male pattern hair loss and benign prostatic hyperplasia (BPH) in adult males. Common side effects of finasteride can include erectile dysfunction, loss of libido, ...

Benign prostatic hyperplasia (BPH) refers to a benign enlargement of the prostate gland. The prostate may eventually increase to a size that is large enough to press against the urethra and bladder ...

Benign Prostatic Hyperplasia Surgical Treatment Market OverviewThe global benign prostatic hyperplasia surgical treatment ...

Despite its importance, the prostate gland in an adult man is only about the size and shape of a walnut and weighs less than 1 ounce (20 to 30 grams). It is located below the bladder, above the pelvic ...